Kiadis Pharma to participate in a panel at Innovation for Health 2019
11 Février 2019 - 05:45PM
Kiadis Pharma to participate in a panel at
Innovation for Health 2019
Amsterdam, The
Netherlands, February 11, 2019 - Kiadis Pharma N.V. ("Kiadis
Pharma" or the "Company") (Euronext Amsterdam and Brussels:
KDS), a clinical-stage biopharmaceutical company, today
announces that it is scheduled to participate in a panel at the
Innovation for Health
2019 Conference and Global
Investor Forum on Thursday, February 14, 2019.
Innovation for Health
February 14, 2019, World Trade Center Rotterdam,
Beursplein 37, Rotterdam, The Netherlands
Arthur Lahr, Chief Executive Officer, will participate in a panel
discussion related to "Building a Winning Team for
Innovation" held from 13:30 - 14:30 CET.
Innovation for Health is one of
the premier events for Health & Life Sciences in the
Netherlands and Belgium. It brings together key players in health
and care, from bench to boardroom, start-up to multinational and
from life sciences to medtech. Held in conjunction with Global
Investor Forum, Innovation for Health brings together over 800
delegates and 60 influential speakers from across industry,
academia, government, finance and patient-organisations with the
purpose to contribute to a sustainable future of healthcare.
For more
information, please contact:
Kiadis Pharma:
Amy Sullivan
Sr. Vice President, Corporate Affairs
a.sullivan@kiadis.com
|
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com
|
About Kiadis Pharma
Kiadis Pharma is developing its lead product
candidate, ATIR101, for use in conjunction with haploidentical
(genetically half-matched) hematopoietic stem-cell transplantations
(HSCT) for adult blood cancers to address key limitations of
haploidentical HSCT, without prophylactic immunosuppression and its
associated morbidity and mortality. Based on the positive results
from the single dose Phase 2 CR-AIR-007 study, the Company
submitted a marketing authorization application to the European
Medicines Agency in April 2017 for approval of ATIR101 as an
adjunctive treatment in haploidentical HSCT for high risk adult
hematological malignancies. If the product is conditionally
approved, Kiadis Pharma intends to launch ATIR101 through its own
commercial organization in a first EU member state in the second
half of 2019.
In December 2017,
Kiadis Pharma commenced an international, multicenter, randomized
and controlled Phase 3 clinical trial of ATIR101 against the
Post-Transplant Cyclophosphamide, (PTCy) protocol, the main
protocol used to perform a haploidentical HSCT. The trial will be
performed in 250 patients with acute leukemia and myelodysplastic
syndrome at approximately 50 sites in the United States, Canada,
Europe and certain additional countries. ATIR101 received
regenerative medicine advanced therapy (RMAT) designation from the
FDA in September 2017, which provides benefits that are materially
equivalent to a Breakthrough Therapy designation from the FDA. In
addition, ATIR101 has been granted multiple orphan drug
designations both in the European Union and the United
States.
The Company's
shares are listed on Euronext Amsterdam and Brussels under the
ticker KDS.
Forward Looking
Statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma's
or, as appropriate, Kiadis Pharma's directors' current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, regulation, competition and
technology, can cause actual events, performance or results to
differ significantly from any anticipated development. Forward
looking statements contained in this press release regarding past
trends or activities should not be taken as a representation that
such trends or activities will continue in the future. As a result,
Kiadis Pharma expressly disclaims any obligation or undertaking to
release any update or revisions to any forward-looking statements
in this press release as a result of any change in expectations or
any change in events, conditions, assumptions or circumstances on
which these forward-looking statements are based. Neither Kiadis
Pharma nor its advisers or representatives nor any of its
subsidiary undertakings or any such person's officers or employees
guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking
statements contained in this press release or the actual occurrence
of the forecasted developments. You should not place undue reliance
on forward-looking statements, which speak only as of the date of
this press release.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Kiadis Pharma N. V. via Globenewswire